Titre :

Associations of anticoagulant use with outcome in newly diagnosed glioblastoma

Auteur(s) :

Le Rhun, Emilie [Auteur]
Protéomique, Réponse Inflammatoire, Spectrométrie de Masse (PRISM) - U1192
Genbrugge, Els [Auteur]
Stupp, Roger [Auteur]
Chinot, Olivier L. [Auteur]
Nabors, L. Burt [Auteur]
Cloughesy, Timothy F. [Auteur]
Reardon, David A. [Auteur]
Wick, Wolfgang [Auteur]
Gorlia, Thierry [Auteur]
Weller, Michael [Auteur]

Titre de la revue :

European journal of cancer (Oxford, England . 1990)

Nom court de la revue :

Eur. J. Cancer

Numéro :

101

Pagination :

95-104

Date de publication :

2018-07-20

ISSN :

1879-0852

Mot(s)-clé(s) :

Brain
Prognosis
Heparin
Vitamin K
Survival
Thrombosis
Pulmonary
Embolism
Glioma

Discipline(s) HAL :

Sciences du Vivant [q-bio]

Résumé en anglais : [en]

BACKGROUND: To test the hypothesis that despite bleeding risk, anticoagulants improve the outcome in glioblastoma because of reduced incidence of venous thromboembolic events and modulation of angiogenesis, infiltration ...
Lire la suite >BACKGROUND: To test the hypothesis that despite bleeding risk, anticoagulants improve the outcome in glioblastoma because of reduced incidence of venous thromboembolic events and modulation of angiogenesis, infiltration and invasion. METHODS: We assessed survival associations of anticoagulant use from baseline up to the start of temozolomide chemoradiotherapy (TMZ/RT) (period I) and from there to the start of maintenance TMZ chemotherapy (period II) by pooling data of three randomised clinical trials in newly diagnosed glioblastoma including 1273 patients. Progression-free survival (PFS) and overall survival (OS) were compared between patients with anticoagulant use versus no use; therapeutic versus prophylactic versus no use; different durations of anticoagulant use versus no use; anticoagulant use versus use of anti-platelet agents versus neither anticoagulant nor anti-platelet agent use. Cox regression models were stratified by trial and adjusted for baseline prognostic factors. RESULTS: Anticoagulant use was documented in 75 patients (5.9%) in period I and in 104 patients (10.2%) in period II. Anticoagulant use during period II, but not period I, was associated with inferior OS than no use on multivariate analysis (p = 0.001, hazard ratio [HR] = 1.52, 95% confidence interval [CI]: 1.18-1.95). No decrease in OS became apparent when only patients with prophylactic anticoagulant use were considered. No survival association was established for anti-platelet agent use. CONCLUSIONS: Anticoagulant use was not associated with improved OS. Anticoagulants may not exert relevant anti-tumour properties in glioblastoma.Lire moins >

Langue :

Anglais

Audience :

Internationale

Vulgarisation :

Non

Établissement(s) :

INSERM
Université de Lille

Collections :

• Protéomique, Réponse Inflammatoire, Spectrométrie de Masse (PRISM) - U1192

Date de dépôt :

2022-06-15T13:58:35Z
2023-04-21T10:23:50Z